344 related articles for article (PubMed ID: 22370716)
1. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients.
Jung EJ; Santarpia L; Kim J; Esteva FJ; Moretti E; Buzdar AU; Di Leo A; Le XF; Bast RC; Park ST; Pusztai L; Calin GA
Cancer; 2012 May; 118(10):2603-14. PubMed ID: 22370716
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
3. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer.
Dominici LS; Negron Gonzalez VM; Buzdar AU; Lucci A; Mittendorf EA; Le-Petross HT; Babiera GV; Meric-Bernstam F; Hunt KK; Kuerer HM
Cancer; 2010 Jun; 116(12):2884-9. PubMed ID: 20564395
[TBL] [Abstract][Full Text] [Related]
4. Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.
Müller V; Gade S; Steinbach B; Loibl S; von Minckwitz G; Untch M; Schwedler K; Lübbe K; Schem C; Fasching PA; Mau C; Pantel K; Schwarzenbach H
Breast Cancer Res Treat; 2014 Aug; 147(1):61-8. PubMed ID: 25086636
[TBL] [Abstract][Full Text] [Related]
5. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer.
Cha C; Ahn SG; Kim D; Lee J; Park S; Bae SJ; Kim JY; Park HS; Park S; Kim SI; Park BW; Jeong J
Int J Cancer; 2021 Oct; 149(8):1585-1592. PubMed ID: 34213778
[TBL] [Abstract][Full Text] [Related]
6. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
Zhang Z; Zhang L; Yu G; Sun Z; Wang T; Tian X; Duan X; Zhang C
Cancer Chemother Pharmacol; 2020 Dec; 86(6):761-772. PubMed ID: 33068176
[TBL] [Abstract][Full Text] [Related]
7. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer.
Gong C; Yao Y; Wang Y; Liu B; Wu W; Chen J; Su F; Yao H; Song E
J Biol Chem; 2011 May; 286(21):19127-37. PubMed ID: 21471222
[TBL] [Abstract][Full Text] [Related]
8. Modulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancer.
Le XF; Almeida MI; Mao W; Spizzo R; Rossi S; Nicoloso MS; Zhang S; Wu Y; Calin GA; Bast RC
PLoS One; 2012; 7(7):e41170. PubMed ID: 22829924
[TBL] [Abstract][Full Text] [Related]
9. MiR-129-5p Sensitizes the Response of Her-2 Positive Breast Cancer to Trastuzumab by Reducing Rps6.
Lu X; Ma J; Chu J; Shao Q; Zhang Y; Lu G; Li J; Huang X; Li W; Li Y; Ling Y; Zhao T
Cell Physiol Biochem; 2017; 44(6):2346-2356. PubMed ID: 29258115
[TBL] [Abstract][Full Text] [Related]
10. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-21 as a predictor and prognostic factor for trastuzumab therapy in human epidermal growth factor receptor 2-positive metastatic breast cancer.
Badr M; Said H; Louka ML; Elghazaly HA; Gaballah A; Atef Abd El Mageed M
J Cell Biochem; 2019 Mar; 120(3):3459-3466. PubMed ID: 30246355
[TBL] [Abstract][Full Text] [Related]
12. Serum microRNA-21 predicted treatment outcome and survival in HER2-positive breast cancer patients receiving neoadjuvant chemotherapy combined with trastuzumab.
Liu B; Su F; Lv X; Zhang W; Shang X; Zhang Y; Zhang J
Cancer Chemother Pharmacol; 2019 Nov; 84(5):1039-1049. PubMed ID: 31482230
[TBL] [Abstract][Full Text] [Related]
13. Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy.
Kim JW; Kim JH; Im SA; Lee KH; Kim JS; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1023-9. PubMed ID: 24036907
[TBL] [Abstract][Full Text] [Related]
14. Association between the HER2 Ile655Val polymorphism and response to trastuzumab in women with operable primary breast cancer.
Han X; Diao L; Xu Y; Xue W; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Ann Oncol; 2014 Jun; 25(6):1158-64. PubMed ID: 24608202
[TBL] [Abstract][Full Text] [Related]
15. Protein kinase A activation confers resistance to trastuzumab in human breast cancer cell lines.
Gu L; Lau SK; Loera S; Somlo G; Kane SE
Clin Cancer Res; 2009 Dec; 15(23):7196-206. PubMed ID: 19920112
[TBL] [Abstract][Full Text] [Related]
16. Plasma microRNAs Predict Chemoresistance in Patients With Metastatic Breast Cancer.
Shao B; Wang X; Zhang L; Li D; Liu X; Song G; Cao H; Zhu J; Li H
Technol Cancer Res Treat; 2019 Jan; 18():1533033819828709. PubMed ID: 30786836
[TBL] [Abstract][Full Text] [Related]
17. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
[TBL] [Abstract][Full Text] [Related]
18. The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers.
Chen W; Cai F; Zhang B; Barekati Z; Zhong XY
Tumour Biol; 2013 Feb; 34(1):455-62. PubMed ID: 23238818
[TBL] [Abstract][Full Text] [Related]
19. ER-poor and HER2-positive: a potential subtype of breast cancer to avoid axillary dissection in node positive patients after neoadjuvant chemo-trastuzumab therapy.
Li JW; Mo M; Yu KD; Chen CM; Hu Z; Hou YF; Di GH; Wu J; Shen ZZ; Shao ZM; Liu GY
PLoS One; 2014; 9(12):e114646. PubMed ID: 25504233
[TBL] [Abstract][Full Text] [Related]
20. Pathologic Complete Response in HER2-Positive Breast Cancer Patients Receiving Trastuzumab in Neoadjuvant Setting.
Sheikh F; Nazir A; Yasmeen S; Badar F; Ahmad U; Siddiqui N
J Coll Physicians Surg Pak; 2019 Feb; 29(2):159-163. PubMed ID: 30700356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
